Oculis Holding AG (OCS) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.26 (+0.24% 1D, market cap $507.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OCS ranks #344 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AQST (Aquestive Therapeutics Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $507.1M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, OCS leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).
For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #344 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.4% FCF Margin ($14.2M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While OCS currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($9.65) and Max Pain ($8.67) forces dealer call-delta covering toward $36.19.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Oculis Holding AG (OCS) advanced +0.24% to $8.26, trading at 4% of its 52-week range ($7.11 – $34.47). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holdi
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: L
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum. Nákvæm
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trialsPrecision Medicine Approach in a Large
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OCS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OCS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Oculis Holding AG (OCS) ranks #344 by composite RQD confidence (47/100, grade D) and #448 by equity capitalization ($507.5M). Within this direct 5-issuer industry benchmark cohort, OCS leads on earnings valuation at N/A trailing P/E, while AQST leads on capital efficiency and profitability with -35.0% ROIC and 58.3% gross margin. OCS currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OCS
ACTIVE
Oculis Holding AG | D | 47/100 | — | — | — | +0.24% | $507.5M | Benchmark Subject |
| AQST Aquestive Therapeutics Inc. | E | 18/100 | — | 58.3% | -35.0% | -3.71% | $507.1M | /aqst-vs-ocs → |
| PHAT Phathom Pharmaceuticals Inc. | E | 34/100 | — | 87.1% | -35.0% | -7.72% | $503.2M | /phat-vs-ocs → |
| INDP Indaptus Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -7.48% | $513.0M | /indp-vs-ocs → |
| DMAC DiaMedica Therapeutics Inc. | D | 44/100 | — | — | -35.0% | -2.84% | $513.4M | /dmac-vs-ocs → |
Oculis Holding AG (OCS) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $507.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Oculis Holding AG (NASDAQ: OCS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $8.26 (+0.24% 1D, market cap $507.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OCS ranks #344 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OCS carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AQST (Aquestive Therapeutics Inc.) holds a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $507.1M) and PHAT (Phathom Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $503.2M). Among the 5-stock peer group, OCS leads on earnings multiple (N/A) while AQST leads on capital efficiency (-35.0% ROIC).
For Oculis Holding AG (OCS), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #344 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
OCS last traded at $8.26 (+0.24% on volume of 309,711 shares), positioning the stock -14.40% below its 50-day simple moving average ($9.65) and -55.92% below its 200-day simple moving average ($18.74). Across its 52-week range of $7.11 to $34.47, OCS sits at the 4.2% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.23 to $9.29).
Why OCS Stock advanced +0.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, OCS scores 47 out of 100, a D grade, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 12/20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 5/20 (institutional accumulation and options positioning); Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are Whale 13F Flow and Macro Regime Fit, while the balance sheet is the strongest. The cash-generation pillar is weak because the source reports zero ROIC and zero FCF yield, meaning the rating provides no evidence of current cash-based return to shareholders. The balance sheet metrics (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) are the main reason the score is not lower, which suggests financial solvency is less of a concern than the lack of earnings power and the institutional and insider signals. The rating label itself flags distribution risk. Upside drivers would need to come from outside the scored factors; the source data does not identify any.
Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or bottlenecks are identified in the source data. Sector classification is Health Care and industry is Biotechnology: Pharmaceutical Preparations. Beyond this classification, no ripple effects can be drawn from the source.
Real-time company headlines, analyst actions, and sector developments for Oculis Holding AG (OCS) • Click "Debate This Headline" to argue it in the Roar Pit below
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holdi
HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and maintains $39 price target.
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological ev
Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological
Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: L
Welcome to the OCS (Oculis Holding AG) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on OCS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Oculis Holding AG expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on OCS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.24 (52-wk range $7.11 - $34.47), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).